# Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC

> **NCT03061058** · PHASE3 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 240 (estimated)

## Conditions studied

- Stomach Neoplasms
- Chemotherapy Effect
- Chemotherapeutic Toxicity

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin
- **DRUG:** Cisplatin
- **DRUG:** Irinotecan
- **DRUG:** Pemetrexed
- **DRUG:** S1

## Key facts

- **NCT ID:** NCT03061058
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04-01
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2017-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061058, "Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03061058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*